Bromocriptine-responsive Cushing's disease; clinical and biochemical remission accompanied by amelioration of impaired ocular movement

Internal Medicine

Volumn 46, Issue 14, 2007, Pages 1117-1122

  Kawamura, Mitsunobu ^a   Nakano, Tae ^a   Miki, Hiroko ^a   Tamura, Yuriko ^a   Miyazaki, Shigeru ^a   Hirata, Yukio ^b  

^a TOKYO TEISHIN HOSPITAL   (Japan)

^b TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

Author keywords

Bromocriptine; Cushing's disease; Impaired ocular movement; Type 2 diabetes

Indexed keywords

BROMOCRIPTINE; CORTICOTROPIN; CORTICOTROPIN RELEASING FACTOR; DESMOPRESSIN; DEXAMETHASONE; HYDROCORTISONE;

AGED; ARTICLE; BIOCHEMISTRY; CASE REPORT; CAVERNOUS SINUS; CIRCADIAN RHYTHM; CUSHING DISEASE; DRUG MEGADOSE; ENDOCRINE SYSTEM EXAMINATION; EYE MOVEMENT DISORDER; FEMALE; GAMMA KNIFE RADIOSURGERY; HUMAN; HYPOPHYSIS TUMOR; LOW DRUG DOSE; NUCLEAR MAGNETIC RESONANCE IMAGING; PTOSIS; REMISSION; TREATMENT DURATION; TREATMENT OUTCOME; TUMOR VOLUME;

ADENOMA; AGED; BROMOCRIPTINE; FEMALE; HORMONE ANTAGONISTS; HUMANS; OCULAR MOTILITY DISORDERS; PITUITARY ACTH HYPERSECRETION; PITUITARY NEOPLASMS; REMISSION INDUCTION; TREATMENT OUTCOME;

EID: 34548427047     PISSN: 09182918     EISSN: 13497235     Source Type: Journal    
DOI: 10.2169/internalmedicine.46.6436     Document Type: Article

References (24)

1. Boscaro M, Barzon L, Fallo F, Sonino N. Cushing's syndrome. The Lancet 357: 783-791, 2001.
2. Miller JW, Crapo L. The medical treatment of Cushing's syndrome. Endocr Rev 14: 443-458, 1993.
3. Sonino N, Boscaro M. Medical therapy for Cushing's disease. Endocinol Metab Clin North Am 28: 211-222, 1999.
4. Nieman LK. Medical therapy of Cushing's disease. Pituitary 5: 77-82, 2002.
5. Kreutzer J, Fahlbusch R. Diagnosis and treatment of pituitary tumors. Curr Opin Neurol 17: 693-703, 2004.
6. Ambrosi B, Dall'Asta C, Cannavo S, Libe R, Vigo T, Epaminonda P, Chiodini I, Ferrero S, Trimarchi F, Arosio M, Beck-Peccoz P. Effects of chronic administration of PPAR-gamma ligand rosiglita-zone in Cushing's disease. Eur J Endocrinol 151: 173-178, 2004.
7. Kennedy AL, Sheridan B, Montgomery DAD. ACTH and cortisol response to bromocriptine, and results of long-term therapy, in Cushing's disease. Acta Endocr 89: 461-468, 1978.
8. Boscaro M, Benato M, Mantero F. Effect of bromocriptine in pituitary-dependent Cushing's syndrome. Clin Endocr 19: 485-491, 1983.
9. Verde G, Loli P, Berselli ME, et al. Cushing's disease and marked hyperprolactinemia in a patient with a pituitary macroadenoma: effectiveness of bromocriptine treatment. J Endocrinol Invest 7: 51-54, 1984.
10. Atkinson AB, Kennedy AL, Sheridan B. Six year remission of ACTH-dependent Cushing's syndrome using bromocriptine. Post-grad Med J 61: 239-242, 1985.
11. Koppeschaar HP, Croughs RJ, Thijssen JH, Schwarz F. Response to neurotransmitter modulating drugs in patients with Cushing's disease. Clin Endocrinol (Oxf) 25: 661-667, 1986.
12. McKenna MJ, Linares M, Mellinger RC. Prolonged remission of Cushing's disease following bromocriptine therapy. Henry Ford Hosp Med J 35: 188-191, 1987.
13. Hale AC, Coates PJ, Doniach I, Howlett TA, Grossman A, Rees LHA, Besser GM. A bromocriptine-responsive corticotroph adenoma secreting alpha-MSH in a patient with Cushing's disease. Clin Endocrinol (Oxf) 28: 215-223, 1988.
14. Sumiya N, Hiramatsu K, Arimori S. A case of Cushing's disease successfully treated with bromocriptine. Jpn J Med 29: 185-190, 1990.
15. Tokui M, Maruyama H, Kanda N, et al. A case of an elderly Cushing syndrome in which the small quantity of bromocriptine has succeeded for a long period. Folia Endocrinol J 71: 777, 1995 (in Japanese).
16. Kamoi H, Toyama T, Tanaka K. A case of the Cushing disease which bromocriptine had a marked effectiveness. Folia Endocrinol J 69: 720, 1993 (in Japanese).
17. Kaneko K, Toyama T, Morishita H, Nakajima U. Bromocriptine treatment for the Cushing disease - the effect of long-term medication by small dose. Folia Endocrinol J 69: 385, 1993 (in Japanese).
18. Yoshida A, Ohmura M, Iizuka T, Nishikawa T. A case of the Cushing disease accompanied by high prolactinemia which is remitting by bromocriptine for a long period. ACTH R P 10: 245-250, 1999 (in Japanese).
19. Ishibashi M, Yamaji T. Direct effects of thyrotropin-releasing hormone, cyproheptadine, and dopamine on adrenocorticotropin secretion from human corticotroph adenoma cells in vitro. J Clin Invest 68: 1018-1027, 1981.
20. Pivonello R, Ferone D, de Herder WW, et al. Dopamine receptor expression and function in human normal adrenal gland and adrenal tumors. J Clin Endocrinol Metab 89: 4493-4502, 2004.
21. Lamberts SW, de Lange SA, Stefanko SZ. Adrenocorticotropin-secreting pituitary adenomas originate from the anterior or the intermediate lobe in Cushing's disease: differences in the regulation of hormone secretion. J Clin Endocrinol Metab 54: 286-291, 1982.
22. Croughs RJ, Koppeschaar HP, van't Verlaat JW, McNicol AM. Bromocriptine-responsive Cushing's disease associated with anterior pituitary corticotroph hyperplasia or normal pituitary gland. J Clin Endocrinol Metab 68: 495-498, 1989.
23. McNicol AM, Teasdale GM, Beastall GH. A study of corticotroph adenomas in Cushing's disease: no evidence of intermediate lobe origin. Clin Endocrinol (Oxf) 24: 715-722, 1986.
24. Bevan JS, Webster J, Burke CW, Scanlon MF. Dopamine agonists and pituitary tumor shrinkage. Endocr Rev 13: 220-240, 1992.